RWJ 38063 | 216252-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: RWJ 38063
• 英文别名: N-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]-2-oxo-1-piperidineacetamide；Unii-M7ias8PR23；2-(2-oxopiperidin-1-yl)-N-[2-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]ethyl]acetamide
• CAS: 216252-56-1
• 化学式: C₂₂H₃₄N₄O₃
• 分子量: 402.537
• InChiKey: IIRJWNCOXHFIBK-UHFFFAOYSA-N

物化性质

• 沸点：
  644.8±55.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  65.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  RWJ 38063 、 氢碘酸 在 乙酸乙酯 、 甲醇 、 product 作用下， 以 乙酸乙酯 为溶剂， 反应 16.5h， 生成 N-{2-[4-(2-(2-propoxy)phenyl)-1-piperazinyl]ethyl}-2-(2-oxo-piperidin-1-yl)acetamide Hydroiodide
  参考文献：
  名称：

  Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide

  摘要：

  本发明涉及一种新型的N-[2-[4-[2-(1-甲基乙氧基)苯基]-1-哌嗪基]乙基]-2-氧代-1-哌嗪乙酰胺的固体盐形式及其制备方法。

  公开号：

  US20020082421A1
• 作为产物：
  描述：

  2-(1-methylethoxy)phenyl-1-piperazine 在 4-二甲氨基吡啶 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 甲基肼 作用下， 以 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 15.0h， 生成 RWJ 38063
  参考文献：
  名称：

  Novel arylpiperazines as selective α 1 -adrenergic receptor antagonists

  摘要：

  A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha(1a) adrenergic receptor (alpha(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha(1)-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00169-4

文献信息

• [EN] SOLID SALT FORMS OF N-[2-[4-[2-(1-METHYLETHOXY)PHENYL]-1-PIPERAZINYL]ETHYL]-2-OXO-1-PIPERIDINEACETAMIDE<br/>[FR] NOUVELLES FORMES SOLIDES DE SEL DE N-[2-[4-[2-(1-METHYLETHOXY)PHENYL]-1-PIPERAZINYL]ETHYL]-2-OXO-1-PIPERIDINEACETAMIDE
  申请人：——

  公开号：WO2002022582A3

  公开（公告）日：2002-10-17

  [EN] The present invention relates to novel solid salt forms of N-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]-2-oxo-1-piperidineacetamide and processes for their preparation.
  [FR] La présente invention concerne des formes solides de sel de N-[2-[4-[2-(1-méthyléthoxy)phényl]-1-pipérazinyl]éthyl]-2-oxo-1-pipéridineacétamide et leurs procédés de préparation.
• [EN] NOVEL SOLID SALT FORMS OF N-[2-[4-[2-(1-METHYLETHOXY)PHENYL]-1-PIPERAZINYL]ETHYL]-2-OXO-1-PIPERIDINEACETAMIDE<br/>[FR] NOUVELLES FORMES SOLIDES DE SEL DE N-[2-[4-[2-(1-METHYLETHOXY)PHENYL]-1-PIPERAZINYL]ETHYL]-2-OXO-1-PIPERIDINEACETAMIDE
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2002022582A2

  公开（公告）日：2002-03-21

  The present invention relates to novel solid salt forms of N-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]-2-oxo-1-piperidineacetamide and processes for their preparation.
• Novel arylpiperazines as selective α 1 -adrenergic receptor antagonists
  作者：Xiaobing Li、William V Murray、Linda Jolliffe、Virginia Pulito

  DOI：10.1016/s0960-894x(00)00169-4

  日期：2000.5

  A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha(1a) adrenergic receptor (alpha(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha(1)-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.
• Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide
  申请人：——

  公开号：US20020082421A1

  公开（公告）日：2002-06-27

  The present invention relates to novel solid salt forms of N-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]-2-oxo-1-piperidineacetamide and processes for their preparation.

  本发明涉及N-[2-[4-[2-(1-甲基乙氧基)苯基]-1-哌嗪基]乙基]-2-氧代-1-哌啶乙酰胺的新型固体盐形式及其制备方法。